Recent evidence has suggested that angiotensin IV (AngIV) and its receptor (AT4R) can be potential therapeutic targets [33,34], since interventions on its signaling improved cognition and vascular flow in the brain of Alzheimer’s disease mouse models [35,36]. The gene discussed is AGT; the disease is early-onset autosomal dominant Alzheimer disease.